Urolithin A Evidence by Cancer Type

This section groups the Urolithin A oncology evidence into focused cancer-type pages as the evidence base becomes strong enough to support them properly.

That structure keeps each cancer page easier to navigate and makes future updates simpler.

Available pages

• Colorectal Cancer — strongest current evidence, including Wnt signalling, AKT1-related immune effects, and chemotherapy sensitisation

• Pancreatic Cancer — one of the strongest mechanistic settings, with KRAS-pathway relevance, stromal remodelling, and anti-PD-1 sensitisation data

• Prostate Cancer — most clinically advanced evidence, including androgen-receptor signalling, NK-cell data, and the active phase II trial

• Breast Cancer — subtype-based evidence across ER-positive, triple-negative, and HER2-positive contexts

• Endometrial Cancer — ERα and ERβ remodelling, G2/M arrest, and one of the cleaner hormone-biology settings for Urolithin A

• Glioblastoma — blood-brain-barrier penetration, Sirt1-FOXO1 signalling, and tumour-microenvironment findings

• Liver Cancer (HCC) — direct HCC cell-line findings plus wider hepatoprotective and gut-liver-axis relevance in chronic liver disease

• Lung Cancer — multiple independent NSCLC mechanisms, including EMT inhibition, autophagy-linked mTOR suppression, and in vivo xenograft evidence

• Osteosarcoma — early anti-metastatic evidence focused on migration, invasion, and MMP2/MMP9 suppression

• Bladder Cancer — unusually strong UMUC3 sensitivity, G2/M arrest, apoptosis, and plausible urinary-exposure relevance

If a cancer type is not listed here yet, it can be added later as the evidence base grows.

Key References

Urolithin A research overview and oncology applications
https://pmc.ncbi.nlm.nih.gov/articles/PMC12188533/

Urolithin A in pancreatic cancer models and combination research
https://aacrjournals.org/mct/article/18/2/301/168585/Urolithin-A-a-Novel-Natural-Compound-to-Target